KRAS and cancer: Following a three-hour treatment on mutant KRASG12D cancer cell lines HPAC (pancreatic) and GP2D (colorectal), MRTX1133 caused inhibition (concentration-dependent) of key signaling molecules in the KRAS pathway, including phospho-ERK (pERK) [38,39], with IC50 values ranging from 0.6 nM to 13.7 nM (median IC50: 6.1 nM).